Importantly, a BRAF/MEK inhibitor-resistant but high-AXL-expressing tumor sub-population was killed by the anti-AXL ADC, while BRAF/MEK inhibition was specifically cytotoxic for the low-AXL-expressing tumor cells [86]. The gene discussed is BRAF; the disease is neoplasm.